期刊文献+

化疗所致的特殊皮肤改变:病例报道及文献复习 被引量:5

Specific skin changes caused by chemotherapy : cases report and literature review
下载PDF
导出
摘要 目前中国居民的首位病死原因仍是癌症,其发病率和死亡率逐年升高,化疗是癌症患者主要的全身治疗手段。皮肤毒性则是化疗常见的副作用之一,由于化疗后的皮肤毒性发生不容易危及生命,所以常被忽视,但却常常影响患者的生活质量,甚至导致药物减量和治疗的中断,最终影响化疗疗效。现将我科诊治的4例化疗药物所致罕见的皮肤改变报道如下并作相关文献复习。 Cancer has remained to be the first cause to death for Chinese residents, with its incidence and mortality increasing year by year. Chemotherapy is the main systemic therapy for cancer patients, which frequently causes skin toxicity. This side effect hardly poses threats to lives, thus often neglected. However, skin toxicity usually influences the quality of life and leads to the decrease or pause of chemical drugs, which harms the curative effect. Hereby we report four rare skin changes led by chemotherapy in our department and review the relevant articles.
出处 《岭南现代临床外科》 2016年第5期564-569,共6页 Lingnan Modern Clinics in Surgery
基金 国家自然科学基金(81372819 81572596) 教育部博士点基金(20120171110075) 中山大学青年教育重点培育项目(13ykzd14) 广州市科技计划(2014J4100170)
关键词 化疗 皮肤 副作用 Chemotherapy Skin Side effect
  • 相关文献

参考文献1

二级参考文献26

  • 1Goss GD, O'Callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-ceU lung cancer: results of the NCIC CTG BR19 study.J Clin Oncol, 2013, 31 (27): 3320-3326.
  • 2Kelly K, Altorki N, Eberhardt W, et al. A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results.J Clin Oncol, 2014, 32: abstr 7501.
  • 3Pennell NA, NeaI JW, chart JE, et al. SELECT: a multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC. ASCO Annual Meeting Proceedings, 2014, 32( 15_suppl): 7514.
  • 4Ready N, Janne PA, Bogart J, et al. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.J Thorac Oncolj 2010, 5(9): 1382-1390.
  • 5Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S00Z3. J Clin Oncol, 2008, 26(15): 2450-24S6.
  • 6Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small- cell lung cancer (OPTIMAL, CTONG-080Z): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12(8): 735-742.
  • 7Wu YL, Lee JS, Thongprasert S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol, 2013, 14(8): 777-786.
  • 8Tsai CM, Lai CL, Chiu CH, et al. Maintenance therapy with gefitinib (G)/ pemetrexed (P) versus P alone after induction therapy with P/platinumfor metastatic lung adenocarcinoma (MLADC) harboring no sensitizing epidermal growth factor receptor mutation (sEGFRm): a phase II multicenter randomized open-label study (GENIUS trial). ASCO Annual Meeting Proceedings, 2015, 33 (1S_supp1): 8043.
  • 9Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N EnglJ Med, 2006, 355(24): 2542-2550.
  • 10Reck M, yon Pawel Jj Zatloukal P, et aL Overall survival with cisplatin- gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAIL). Ann Oncol, 2010, 21 (9): 1804-1809.

共引文献14

同被引文献44

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部